Nuedexta, also known by its generic name dextromethorphan hydrobromide and quinidine sulfate, is classified as a medication used to treat pseudobulbar affect (PBA) [1]. PBA is a neurological condition characterized by involuntary outbursts of laughing or crying that are often disproportionate or contrary to how one feels [2]. Nuedexta works by targeting the brain's glutamate pathways, which are thought to be involved in PBA [3].
How Does Nuedexta Work to Treat PBA?
Nuedexta contains two active ingredients: dextromethorphan and quinidine [1]. Dextromethorphan is an NMDA receptor antagonist that also has sigma-1 receptor agonist activity [4]. Quinidine inhibits the enzyme CYP2D6, which metabolizes dextromethorphan [4]. By inhibiting CYP2D6, quinidine increases the blood levels of dextromethorphan, thereby enhancing its therapeutic effects on PBA [4].
What is Pseudobulbar Affect (PBA)?
Pseudobulbar affect is a neurological symptom that can occur after certain conditions that affect the brain, such as stroke, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), and Alzheimer's disease [2][5]. It is important to distinguish PBA from emotional lability or mood disorders, as PBA involves involuntary and uncontrollable episodes of crying or laughing [2].
When Does Nuedexta Patent Exclusivity Expire?
Information on Nuedexta's patent exclusivity and potential for generic entry is available through patent watch services. DrugPatentWatch.com tracks patent expirations and regulatory exclusivities for many drugs, including Nuedexta [6]. While specific patent expiry dates can be complex due to various patent types and potential legal challenges, general information on such timelines can be found through specialized resources [6].
Who Manufactures Nuedexta?
Nuedexta is manufactured by Acadia Pharmaceuticals Inc. [1].
What Are the Risks and Side Effects of Nuedexta?
Like all medications, Nuedexta carries potential risks and side effects. Common side effects reported include diarrhea, cough, and urinary tract infection [1]. More serious side effects can occur, and individuals should consult their healthcare provider for a complete list of risks and contraindications [1]. The drug carries a boxed warning regarding potential liver enzyme elevations and advises monitoring [1].
Are There Alternatives for Treating PBA?
While Nuedexta is an approved treatment for PBA, other approaches may be considered depending on the underlying cause and individual patient needs. These can include behavioral therapies and management of the underlying neurological condition [5]. Research continues into other pharmacological interventions for PBA.
How is Nuedexta Administered and Dosed?
Nuedexta is administered orally [1]. The typical starting dose is one capsule every 12 hours [1]. Dosage adjustments may be necessary based on individual response and tolerance [1].
*
**Sources:
[1] https://www.nuedexta.com/
[2] https://www.nuedexta.com/what-is-pba
[3] https://www.nuedexta.com/how-nuedexta-works
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314091/
[5] https://www.nuedexta.com/pba-causes-and-symptoms
[6] https://www.drugpatentwatch.com/